Horneff G, et al. - This study details the experience with etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors anakinra and canakinumab (IL-1i) in systemic onset juvenile idiopathic arthritis (sJIA), using data from the German Biologics register (BiKeR). Findings reported a gain of significant response to treatment in a large proportion of patients, especially when treated with TOC or IL-1is. As a result of 6 months treatment, Juvenile Disease Activity Score (JADAS) remission was reached by up to half of patients while up to two-thirds reached JADAS minimal disease activity. Though used in the past, ETA was obviously less effective and with respect to its use in systemic juvenile idiopathic arthritis in Germany, a decline has been reported.